The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Oral Zinc in Macular Degeneration
Abstract
Macular degeneration associated with age and drusen, an important cause of severe visual loss in older persons, is of unknown cause. The sensory retina and retinal pigment epithelium, which are cell layers in zinc, appear to be prominently involved in the disease process. Because zinc plays a role in the metabolic function of several important enzymes in the chorioretinal complex, we undertook a prospective, randomized, double-masked, placebo-controlled investigation of the effects of oral zinc administration on the visual acuity outcome in 151 subjects with drusen or macular degeneration. Although some eyes in the zinc-treated group lost vision, this group had significantly less visual loss than the placebo group after a follow-up of 12 to 24 months. This is the first controlled oral intervention study to show a positive, if limited, treatment effect in macular degeneration, a major public health problem. Because of the pilot nature of the study and the possible toxic effects and complications of oral zinc administration, widespread use of zinc in macular degeneration is not now warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One small, randomized, 2-year, placebo-controlled clinical trial of zinc supplementation found a statistically significant reduction in visual acuity loss in the zinc-treated group and recommended a more definitive trial before a general recommendation could be made for zinc supplementation in those at risk of vision loss from advanced AMD. 27”
In the citing paper
“A small randomized trial, completed before AREDS began, suggested a benefit of large doses of zinc on visual acuity in persons with AMD.27”
Citations
Cites
Senile macular degeneration: a case-control study
HYMAN, L. G., LILIENFELD, A. M., FERRIS, F. L., & FINE, S. L. (1983) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113629 · Cited by 587
Cited by
Sorted by citations
(2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.10.1417 · Cited by 3,285
“A small randomized trial, completed before AREDS began, suggested a benefit of large doses of zinc on visual acuity in persons with AMD.(27) For zinc alone, AREDS did not find a statistically significant reduction in the odds of a 15-letter visual acuity loss.”
Background(2013) · JAMA · doi:10.1001/jama.2013.4997 · Cited by 1,355
“A zinc dose of 80 mg was used in the original AREDS formulation because it was the dose used in an earlier trial suggesting efficacy.(17) We tested the AREDS formulation with a lower dose of zinc (25 mg) because data suggested that this may be the maximal level absorbed.”
MethodDietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration
Seddon, J. M. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03520180037032 · Cited by 993
Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies
Ambati, J., Ambati, B. K., Yoo, S. H., Ianchulev, S., & Adamis, A. P. (2003) · Survey of Ophthalmology · doi:10.1016/s0039-6257(03)00030-4 · Cited by 959
Zinc as a Gatekeeper of Immune Function
Weßels, I., Maywald, M., & Rink, L. (2017) · Nutrients · doi:10.3390/nu9121286 · Cited by 809
“In the elderly population, age-related macular degeneration (AMD) is of frequent occurrence and AMD progress, which can result in blindness, can be treated successfully by zinc supplementation [58,59].”
Background
Metadata
- Authors
- Newsome, D. A., Swartz, M., Leone, N. C., Elston, R. C., & Miller, E.
- Affiliations
- Louisiana State University (US)
- University of Utah (US)
- Utah State University (US)
- ORCID
- Elston, R. C.
- Venue
- Archives of Ophthalmology
- Publisher
- American Medical Association (AMA)
- Published
- 1988-02-01
- Volume
- 106
- Issue
- 2
- Pages
- 192-198
- ISSN
- 0003-9950 (ISSN-L)
- OpenAlex
- W2007111898
- Cited by
- 349
- References
- 0
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 2 · 2023: 5 · 2022: 6 · 2021: 5 · 2020: 4 · 2019: 4 · 2018: 6 · 2017: 8 · 2016: 6 · 2015: 9 · 2014: 7 · 2013: 13 · 2012: 14
- FWCI
- 14.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Nursing › Nutrition and Dietetics › Trace Elements in Health
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- macular degeneration, oral zinc supplementation, drusen, age-related macular degeneration, visual acuity, retinal pigment epithelium, zinc toxicity, blindness prevention
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Clinical Trials as Topic, Double-Blind Method, Female, Fluorescein Angiography, Humans, Macular Degeneration, Male, Middle Aged, Prospective Studies, Random Allocation, Zinc
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
